Venture Funding Deals: Orchard Brings Total To $291m
New $150m Series C round brings Orchard's tally to nearly $300m, just four months after the start-up acquired a portfolio of gene therapy candidates from GSK and eight months after a $110m round. Gritstone closed a Series C then announced an IPO filing, plus more late-summer VC rounds.
You may also be interested in...
The company isn't relaying any details about its drug targets, but will use the mega-round to take its first candidates into the clinic. Also, RiverVest raises a $184.4m VC fund, Annexon closes a $75m Series C, Takeda lists its stock in the US, and Aptorum goes public.
Public Company Edition: Eli Lilly & Co. wasted no time spinning out its animal health business Elanco, which raised $1.5bn in its public debut. Also, as the biopharma IPO tally rises, Vivo Capital launches a new public life science company fund. Meanwhile, Concordia completes its recapitalization.
Bluebird has been an active deal maker as it looks to add tools, targets and technological capabilities to its R&D engine. A pair of August TCR-focused deals, including the latest with Gritstone, continue that strategy.